RJA
NVS icon

Raymond James & Associates’s Novartis NVS Stock Holding History

Raymond James & Associates’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$59.6M Sell
518,181
-18,426
-3% -$2.09M 0.04% 396
2024
Q2 		$57.1M Buy
536,607
+6,767
+1% +$679K 0.04% 383
2024
Q1 		$51.3M Buy
529,840
+11,435
+2% +$1.17M 0.03% 401
2023
Q4 		$52.3M Buy
518,405
+23
+0% +$2.22K 0.04% 377
2023
Q3 		$52.8M Sell
518,382
-24,235
-4% -$2.46M 0.04% 335
2023
Q2 		$54.8M Sell
542,617
-9,924
-2% -$993K 0.05% 339
2023
Q1 		$50.8M Sell
552,541
-146,609
-21% -$12.8M 0.04% 351
2022
Q4 		$63.4M Sell
699,150
-84,968
-11% -$7.16M 0.06% 290
2022
Q3 		$59.6M Buy
784,118
+21,322
+3% +$1.77M 0.06% 274
2022
Q2 		$64.5M Sell
762,796
-128,085
-14% -$11.2M 0.06% 270
2022
Q1 		$78.2M Buy
890,881
+51,021
+6% +$4.42M 0.07% 255
2021
Q4 		$73.5M Buy
839,860
+11,507
+1% +$955K 0.06% 276
2021
Q3 		$67.7M Sell
828,353
-115
-0% -$10.3K 0.06% 271
2021
Q2 		$75.6M Sell
828,468
-94,313
-10% -$8.4M 0.07% 240
2021
Q1 		$78.9M Sell
922,781
-302,590
-25% -$27.2M 0.08% 218
2020
Q4 		$116M Buy
1,225,371
+65,283
+6% +$5.7M 0.13% 145
2020
Q3 		$101M Sell
1,160,088
-121,681
-9% -$10.5M 0.13% 145
2020
Q2 		$112M Buy
1,281,769
+12,319
+1% +$1.06M 0.15% 125
2020
Q1 		$105M Buy
1,269,450
+62,098
+5% +$5.54M 0.17% 102
2019
Q4 		$114M Buy
1,207,352
+24,154
+2% +$2.17M 0.15% 121
2019
Q3 		$103M Sell
1,183,198
-454,627
-28% -$40.8M 0.14% 133
2019
Q2 		$150M Sell
1,637,825
-98,173
-6% -$8.31M 0.22% 84
2019
Q1 		$150M Buy
1,735,998
+45,881
+3% +$3.68M 0.23% 83
2018
Q4 		$130M Buy
1,690,117
+46,875
+3% +$3.65M 0.23% 84
2018
Q3 		$127M Buy
1,643,242
+440,206
+37% +$32.5M 0.2% 101
2018
Q2 		$81.4M Sell
1,203,036
-74,054
-6% -$5.11M 0.14% 142
2018
Q1 		$92.5M Buy
1,277,090
+3,458
+0.3% +$263K 0.17% 117
2017
Q4 		$95.8M Buy
1,273,632
+58,561
+5% +$4.42M 0.18% 109
2017
Q3 		$93.5M Sell
1,215,071
-31,559
-3% -$2.38M 0.19% 111
2017
Q2 		$93.2M Sell
1,246,630
-757,868
-38% -$53.7M 0.2% 101
2017
Q1 		$133M Buy
2,004,498
+250,957
+14% +$16.7M 0.31% 57
2016
Q4 		$114M Buy
1,753,541
+741,160
+73% +$48.1M 0.29% 59
2016
Q3 		$71.6M Buy
1,012,381
+300,000
+42% +$21.9M 0.2% 113
2016
Q2 		$52.7M Buy
712,381
+79,226
+13% +$5.47M 0.16% 131
2016
Q1 		$41.1M Buy
633,155
+11,855
+2% +$807K 0.14% 158
2015
Q4 		$47.9M Sell
621,300
-20,923
-3% -$1.66M 0.17% 128
2015
Q3 		$52.9M Buy
642,223
+14,679
+2% +$1.31M 0.22% 95
2015
Q2 		$55.3M Buy
627,544
+9,072
+1% +$832K 0.21% 96
2015
Q1 		$54.6M Buy
618,472
+75,300
+14% +$6.68M 0.24% 86
2014
Q4 		$45.1M Buy
543,172
+35,410
+7% +$2.94M 0.22% 94
2014
Q3 		$42.8M Buy
507,762
+34,295
+7% +$2.77M 0.25% 71
2014
Q2 		$38.4M Buy
473,467
+51,130
+12% +$4.02M 0.24% 71
2014
Q1 		$32.2M Buy
422,337
+30,873
+8% +$2.25M 0.22% 73
2013
Q4 		$28.2M Buy
391,464
+25,289
+7% +$1.76M 0.21% 83
2013
Q3 		$25.2M Buy
366,175
+15,601
+4% +$1.03M 0.22% 83
2013
Q2 		$22.2M Buy
+350,574
New +$22.8M 0.21% 93

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Raymond James & Associates's NVS Position: Q3 2024 in Review

Raymond James & Associates reduced its Novartis (NVS) stake by 3.4% in Q3 2024, selling an estimated $2.09M and leaving 518,181 shares worth $59.6M. The position accounts for 0.04% of the portfolio, ranked #396.

Raymond James & Associates first reported a position in NVS in Q2 2013 and has held it in 46 quarters since. The position peaked at $150M in Q1 2019. 1,311 funds tracked by Wall St. Rank hold NVS as of Q3 2024.

  • Raymond James & Associates held 518,181 shares of Novartis worth $59.6M as of Q3 2024.
  • Raymond James & Associates sold 18,426 Novartis shares in Q3 2024, an estimated $2.09M.
  • Novartis made up 0.04% of Raymond James & Associates's portfolio in Q3 2024, its #396 holding.
  • Raymond James & Associates first reported a position in Novartis in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's Novartis position peaked at $150M in Q1 2019.
  • 1,311 funds tracked by Wall St. Rank held Novartis as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.